Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EPAD

- PMLiVE

Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Biotech Eleusis completes promising phase 1 trial

- PMLiVE

Biogen defends aducanumab filing plan amid scepticism

A new look at pivotal trial data described as hard-to-interpret

- PMLiVE

Karuna’s shares spike on schizophrenia drug data

Value leaps to more than $1bn following mid-stage trial results

- PMLiVE

Merck acquires pre-clinical biotech Calporta for up to $576m

Expands into early-stage neurodegeneration research field

- PMLiVE

Otsuka presses on with Alzheimer’s agitation drug

Surprise announcement comes on the heels of phase 3 trial fail

- PMLiVE

China okays Green Valley’s algae-based drug for Alzheimer’s drug

Due to start phase 3 trials in the US and Europe next year

- PMLiVE

Germany’s Vivoryon raises €43m for Alzheimer’s drug trial

Results of European study expected in 2022

- PMLiVE

Biogen and Eisai revive abandoned aducanumab in shock turnaround

Companies plan to file the deserted Alzheimer’s drug with FDA

- PMLiVE

Avanir’s week goes from bad to worse with Alzheimer’s stumble

Suffers a blow as second phase 3 trial misses the mark

Detecting Alzheimer’s ahead of a cure

A focus on promising new research

- PMLiVE

A roadmap to the successful treatment of Alzheimer’s disease

Building on past research to learn more about the disease and how to treat it

What is changing in mental health and dementia care?

Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services

Wilmington Healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links